
Opinion|Videos|September 23, 2024
Data from LEVEL UP Trial with Upadacitnib in Atopic Dermatitis
Jonathan Silverberg, MD, PhD, MPH, reviews findings from the LEVEL UP study investigating upadacitinib in patients with moderate-to-severe atopic dermatitis.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Please discuss Level Up data with upadacitinib that were recently presented at RAD 2024.
- What are clinical implications of these data for everyday practice?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
REMAIN-1: Improved GLP-1-Induced Weight Loss Retention With Revita DMR System
2
SYMPHONY-PE: Early Thrombectomy Improves Pulmonary Embolism Outcomes
3
AXIOMATIC-TKR: Milvexian Decouples Thrombosis, Hemostasis in DVT
4
FDA Grants Obinutuzumab Priority Review as Primary Membranous Nephropathy’s Potential First Therapy
5











































































